6.79
0.17 (2.57%)
| Previous Close | 6.62 |
| Open | 6.68 |
| Volume | 841,554 |
| Avg. Volume (3M) | 1,288,544 |
| Market Cap | 464,282,528 |
| Price / Sales | 15.69 |
| 52 Weeks Range | |
| Earnings Date | 5 Mar 2025 - 10 Mar 2025 |
| Operating Margin (TTM) | -432.95% |
| Diluted EPS (TTM) | -5.74 |
| Current Ratio (MRQ) | 5.73 |
| Operating Cash Flow (TTM) | -247.11 M |
| Levered Free Cash Flow (TTM) | -179.77 M |
| Return on Assets (TTM) | -57.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.70 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.72% |
| % Held by Institutions | 109.25% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Needham, 312.37%) | Buy |
| 28.00 (HC Wainwright & Co., 312.37%) | Buy | |
| Median | 28.00 (312.37%) | |
| Average | 28.00 (312.37%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.46 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 10 Jan 2025 | 28.00 (312.37%) | Buy | 6.94 |
| 11 Dec 2024 | 28.00 (312.37%) | Buy | 8.40 | |
| HC Wainwright & Co. | 12 Dec 2024 | 28.00 (312.37%) | Buy | 7.99 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CURRAN TERRIE | - | 6.79 | -19,109 | -129,750 |
| HENDERSON MOLLY | - | 6.79 | -6,583 | -44,699 |
| NABULSI AZMI | - | 6.79 | -7,886 | -53,546 |
| Aggregate Net Quantity | -33,578 | |||
| Aggregate Net Value ($) | -227,995 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.79 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CURRAN TERRIE | Officer | 21 Jan 2025 | Sell (-) | 19,109 | 6.79 | 129,750 |
| NABULSI AZMI | Officer | 21 Jan 2025 | Sell (-) | 7,886 | 6.79 | 53,546 |
| HENDERSON MOLLY | Officer | 21 Jan 2025 | Sell (-) | 6,583 | 6.79 | 44,699 |
| Date | Type | Details |
|---|---|---|
| 11 Dec 2024 | Announcement | Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets |
| 07 Nov 2024 | Announcement | Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates |
| 04 Nov 2024 | Announcement | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 28 Oct 2024 | Announcement | Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |